scholarly journals Assessing the Diagnostic Value of Plasma-Free DNA in Prostate Cancer Screening

2018 ◽  
Vol 22 (5) ◽  
pp. 331-337 ◽  
Author(s):  
Seyedeh Maryam Seyedolmohadessin ◽  
Mohammad Taghi Akbari ◽  
Zahra Nourmohammadi ◽  
Abbas Basiri ◽  
Gholamreza Pourmand ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Screening ◽  
Prostate Cancer Screening ◽  
Diagnostic Value ◽  
Free Dna

scholarly journals Quantitative and Qualitative Analysis of Circulating Cell-Free DNA Can Be Used as an Adjuvant Tool for Prostate Cancer Screening: A Meta-Analysis

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Changqing Yin ◽  
Changliang Luo ◽  
Wei Hu ◽  
Xu Ding ◽  
Chunhui Yuan ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Qualitative Analysis ◽  
Prostate Cancer Screening ◽  
Meta Analysis ◽  
Specific Antigen ◽  
Diagnostic Value ◽  
Qualitative Assessment ◽  
Cell Free Dna ◽  
Free Dna ◽  
Circulating Cell Free Dna

As part of “liquid biopsy,” lots of literature indicated the potential diagnostic value of circulating cell-free DNA (cfDNA) in the management of prostate cancer (PCa). However, the literature on the accuracy of cfDNA detection in PCa has been inconsistent. Hence, we performed this meta-analysis to assess the diagnostic value of cfDNA in PCa. A total of 19 articles were included in this analysis according to the inclusion and exclusion criteria. We then investigated two main subgroups in this meta-analysis, including qualitative analysis of abnormal level of cfDNA and qualitative analysis of single-gene methylation alterations. Overall, the results of quantitative analysis showed sensitivity of 0.73 (95% CI, 0.62–0.82) and specificity of 0.80 (95% CI, 0.70–0.87), with an area under the curve (AUC) of 0.83 (95% CI, 0.80–0.86). For qualitative assessment, the values were 0.34 (95% CI, 0.22–0.48), 0.99 (95% CI, 0.97–1.00), and 0.91 (95% CI, 0.88–0.93), respectively. Our results suggest the pooled specificity of each subgroup is much higher than the specificity of prostate-specific antigen (PSA). However, they are not recommended for PCa screening alone, because their sensitivities are not higher than the conventional serum biomarkers PSA. We conclude that analysis of cfDNA can be used as an adjuvant tool for PCa screening.

1035: Prevalence of Erectile Dysfunction in a Prostate Cancer Screening Population

2007 ◽  
Vol 177 (4S) ◽  
pp. 342-342
Author(s):  
Jochen Walz ◽  
Georg Salomon ◽  
Paul Perrotte ◽  
Andrea Gallina ◽  
Georg C. Hutterer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Erectile Dysfunction ◽  
Cancer Screening ◽  
Prostate Cancer Screening ◽  
Screening Population

1462: The use of an Upper age Limit in Prostate Cancer Screening

2005 ◽  
Vol 173 (4S) ◽  
pp. 396-396
Author(s):  
Monique J. Roobol ◽  
Claartje Gosselaar ◽  
Fritz H. Schröder
Keyword(s):  
Prostate Cancer ◽  
Cancer Screening ◽  
Prostate Cancer Screening ◽  
Age Limit

435: When is Decreased Prostate Cancer Mortality to be Expected Provided that Efficacious Prostate Cancer Screening is Introduced?

2004 ◽  
Vol 171 (4S) ◽  
pp. 115-115
Author(s):  
Magnus Törnblom ◽  
Henry Eriksson ◽  
Stefan Franzen ◽  
Ove Gustafsson ◽  
Hans Lilja ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Screening ◽  
Cancer Mortality ◽  
Prostate Cancer Screening ◽  
Prostate Cancer Mortality

649: Prostate Cancer Screening in Persons with a Positive Family History

2004 ◽  
Vol 171 (4S) ◽  
pp. 172-173
Author(s):  
Kathleen Herkommer ◽  
Juergen E. Gschwend ◽  
Martina Kron ◽  
Richard E. Hautmann ◽  
Thomas Paiss
Keyword(s):  
Prostate Cancer ◽  
Cancer Screening ◽  
Family History ◽  
Prostate Cancer Screening ◽  
Positive Family History
Sign in / Sign up

Export Citation Format

Share Document